Who are Paxil-CR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lexapro, Prozac, MDD diagnosis and Fluoxetine treatment, Escitalopram (Lexapro), sertraline fluvoxamine, citalopram (SSRI).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paxil-cr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Paxil-CR — Competitive Intelligence Brief

Paxil-CR (Paxil-CR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Neurology.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Paxil-CR (Paxil-CR) — University of Oklahoma. Paxil-CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paxil-CR TARGET	Paxil-CR	University of Oklahoma	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
MDD diagnosis and Fluoxetine treatment	MDD diagnosis and Fluoxetine treatment	University of Pennsylvania	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin Transporter (SERT)
Escitalopram (Lexapro)	Escitalopram (Lexapro)	University of Rochester	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
sertraline fluvoxamine	sertraline fluvoxamine	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
citalopram (SSRI)	citalopram (SSRI)	Fundació Sant Joan de Déu	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

University of Texas Southwestern Medical Center · 3 drugs in this class
Johns Hopkins University · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Fundació Sant Joan de Déu · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paxil-CR — Competitive Intelligence Brief. https://druglandscape.com/ci/paxil-cr. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab